Let’s review the what, when, and why of neutropenia, including management of febrile neutropenia 🥵
🖥️: www.coreimpodcast.com/2025/08/13/n...
Let’s review the what, when, and why of neutropenia, including management of febrile neutropenia 🥵
🖥️: www.coreimpodcast.com/2025/08/13/n...
rising % ESBL is pushing us to use carbapenems for empiric therapy... leading to more resistance (CDiff, CRE)
aminoglycosides have minimal gut penetration = low CDiff risk & protect microbiome 🧵 #1/4 #EMIMCC
rising % ESBL is pushing us to use carbapenems for empiric therapy... leading to more resistance (CDiff, CRE)
aminoglycosides have minimal gut penetration = low CDiff risk & protect microbiome 🧵 #1/4 #EMIMCC
It's just wild garbage 1/n
www.nytimes.com/2025/05/29/w...
It's just wild garbage 1/n
I'm going to put my nickel down.
I think there is a pretty reasonable argument that we should be choosing doxycyline over azithromycin
let's go thru it... (#1/6)
I'm going to put my nickel down.
I think there is a pretty reasonable argument that we should be choosing doxycyline over azithromycin
let's go thru it... (#1/6)
In 2023, the US imported ~$671M in antibiotics, mainly:
🇮🇹 Italy: $207M
🇨🇳 China: $200M
🇩🇰 Denmark: $46M
🇮🇳 India: $33.6M
🇧🇬 Bulgaria: $30.6M
Tariffs won't lower costs
India & China export 58% of ingredients for making antibiotics + 83% for antivirals in US
In 2023, the US imported ~$671M in antibiotics, mainly:
🇮🇹 Italy: $207M
🇨🇳 China: $200M
🇩🇰 Denmark: $46M
🇮🇳 India: $33.6M
🇧🇬 Bulgaria: $30.6M
Tariffs won't lower costs
India & China export 58% of ingredients for making antibiotics + 83% for antivirals in US
Silence=Death Redux: Infectious Diseases, Public Health, and the Imperative to Resist
Viewpoint by @ericmeyerowitz.bsky.social & me
OpenAccess: academic.oup.com/cid/advance-...
Silence=Death Redux: Infectious Diseases, Public Health, and the Imperative to Resist
Viewpoint by @ericmeyerowitz.bsky.social & me
OpenAccess: academic.oup.com/cid/advance-...